Cancer Institute, University Hospital Fundacion Jimenez Diaz, Autonomous University, Madrid.
Medical Oncology Unit, Regional University Hospital Virgen de la Victoria, IBIMA, Málaga.
Ann Oncol. 2017 Dec 1;28(12):2943-2949. doi: 10.1093/annonc/mdx501.
The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.
突变鉴定对于使用抗表皮生长因子受体药物治疗晚期结直肠癌的重要性已得到充分证实。然而，由于周转时间延迟、组织样本质量低、和/或缺乏检测方法的标准化，很大一部分患者在没有了解 Kirsten 大鼠肉瘤和神经母细胞瘤大鼠肉瘤 (RAS) 检测信息的情况下接受了治疗。BEAMing 技术检测循环肿瘤 DNA 中的突变，填补了这一护理空白，使这些患者能够在短时间内接受国际指南推荐的扩展 RAS 检测。此外，OncoBEAM RAS 结直肠癌检测与标准护理组织检测的总体一致性非常高（93.3%）。本文概述了这种微创方法的临床应用和潜在应用，例如早期检测抗表皮生长因子受体治疗的紧急耐药性。如果得到适当实施，BEAMing 技术有望显著提高患者护理质量并改善临床结果。
